Europe responding to gene therapy challenge, but picture remains fragmented

20 May 2019 - Germany, Italy and England using outcomes-based deals. ...

Read more →

ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system

20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...

Read more →

What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?

9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health ...

Read more →

ICER seeks public input for 2020 value assessment framework

2 May 2019 - Accepting Open Input Through 10 June 2019. ...

Read more →

Drug maker Takeda to introduce value-based pricing in Europe

29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...

Read more →

Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes

8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...

Read more →

The perils of value based pricing for prescription drugs

11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...

Read more →

The role of regulators in establishing added benefit of novel therapies

11 April 2019 - Regulators have a role to play in ensuring that there is a solid evidence base to support ...

Read more →

Value-based agreements could disrupt how we pay for new therapies

8 April 2019 - On Tuesday, the Senate Finance Committee will hold its second hearing in a series on drug ...

Read more →

When is the price of a drug unjust? The average lifetime earnings standard

1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...

Read more →

Outcomes based pricing not a panacea for high priced drugs

27 March 2019 - In the battle over the pricing of new drugs, manufacturers and payers have sought to come ...

Read more →

Overview of cost-effectiveness analysis

11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...

Read more →

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

7 March 2019 - To make medicines more affordable, President Trump insists that “foreign freeloading” must end. ...

Read more →

Evaluating Canadians’ values for drug coverage decision making

2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →